HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: thx.2006.073429v1 62/12/1043    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berry, M. Articles by Pavord, I. D Search for Related Content PubMed PubMed Citation Articles by Berry, M. Articles by Pavord, I. D Topic Collections Related Article

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma

Institute for Lung Health, Glenfield Hospital, Leicester, UK

Correspondence to:
Professor I D Pavord, Institute for Lung Health, Glenfield Hospital, Leicester LE3 9QP, UK; ian.pavord{at}uhl-tr.nhs.uk

Background: Non-eosinophilic asthma is a potentially important clinicopathological phenotype since there is evidence that it responds poorly to inhaled corticosteroid therapy. However, little is known about the underlying airway immunopathology and there are no data from placebo-controlled studies examining the effect of inhaled corticosteroids.

Methods: Airway immunopathology was investigated using induced sputum, bronchial biopsies, bronchial wash and bronchoalveolar lavage in 12 patients with symptomatic eosinophilic asthma, 11 patients with non-eosinophilic asthma and 10 healthy controls. The patients with non-eosinophilic asthma and 6 different patients with eosinophilic asthma entered a randomised, double-blind, placebo-controlled crossover study in which the effects of inhaled mometasone 400 µg once daily for 8 weeks on airway responsiveness and asthma quality of life were investigated.

Results: Patients with non-eosinophilic asthma had absence of eosinophils in the mucosa (median 4.4 cells/mm² vs 23 cells/mm² in eosinophilic asthma and 0 cells/mm² in normal controls; p = 0.03) and normal subepithelial layer thickness (5.8 µm vs 10.3 µm in eosinophilic asthma and 5.1 µm in controls, p = 0.002). Non-eosinophilic and eosinophilic asthma groups had increased mast cell numbers in the airway smooth muscle compared with normal controls (9 vs 8 vs 0 cells/mm², p = 0.016). Compared with placebo, 8 weeks of treatment with inhaled mometasone led to less improvement in methacholine PC₂₀ (0.5 vs 5.5 doubling concentrations, 95% CI of difference 1.1 to 9.1; p = 0.018) and asthma quality of life (0.2 vs 1.0 points, 95% CI of difference 0.27 to 1.43; p = 0.008).

Conclusions: Non-eosinophilic asthma represents a pathologically distinct disease phenotype which is characterised by the absence of airway eosinophilia, normal subepithelial layer thickness and a poor short-term response to treatment with inhaled corticosteroids.

Abbreviations: BAL, bronchoalveolar lavage; ECP, eosinophilic cationic protein; FEV₁, forced expiratory volume in 1 s; GMA, glycol methacrylate; IFN, interferon ; IL, interleukin; PC₂₀, concentration of methacholine provoking a 20% fall in FEV₁

Related Article

What do non-eosinophilic asthma and airway remodelling tell us about persistent asthma?

Peter G Gibson
Thorax 2007 62: 1034-1036. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				F. Hollins, D. Kaur, W. Yang, G. Cruse, R. Saunders, A. Sutcliffe, P. Berger, A. Ito, C. E. Brightling, and P. Bradding Human Airway Smooth Muscle Promotes Human Lung Mast Cell Survival, Proliferation, and Constitutive Activation: Cooperative Roles for CADM1, Stem Cell Factor, and IL-6 J. Immunol., August 15, 2008; 181(4): 2772 - 2780. [Abstract] [Full Text] [PDF]

				S. Zuyderduyn, M. B. Sukkar, A. Fust, S. Dhaliwal, and J. K. Burgess Treating asthma means treating airway smooth muscle cells Eur. Respir. J., August 1, 2008; 32(2): 265 - 274. [Abstract] [Full Text] [PDF]

				J. L. Simpson, H. Powell, M. J. Boyle, R. J. Scott, and P. G. Gibson Clarithromycin Targets Neutrophilic Airway Inflammation in Refractory Asthma Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 148 - 155. [Abstract] [Full Text] [PDF]

				P. G Gibson What do non-eosinophilic asthma and airway remodelling tell us about persistent asthma? Thorax, December 1, 2007; 62(12): 1034 - 1036. [Full Text] [PDF]